FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of veterinary internal medicine2019; 33(2); 953-960; doi: 10.1111/jvim.15411

Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991-2017).

Abstract: Prognosis associated with lymphoma in horses is poorly characterized, and treatment is often palliative. Long-term outcome after chemotherapy for horses with lymphoma is not well documented. Objective: To report long-term outcome of horses with lymphoma treated with chemotherapy. Methods: Fifteen equids. Methods: Retrospective case series. Medical record search and call for cases on the ACVIM listserv for horses treated with chemotherapy for lymphoma. Results: Fifteen cases with adequate data were identified. Complete remission was achieved in 5 horses (33.3%), partial response was achieved in 9 equids (60%), and stable disease was achieved in 1 horse. Overall response rate was 93.3% (14/15). Overall median survival time was 8 months (range, 1-46 months). Nine horses experienced a total of 14 adverse effects attributable to chemotherapy. Adverse effects were graded according to the Veterinary Cooperative Oncology Group common terminology criteria for adverse events grading system (grade 1 alopecia, n = 2; grade 1 neutropenia, n = 2; grade 1 lymphopenia, n = 3; grade 1 lethargy, n = 1; grade 2 neurotoxicity, n = 1; grade 2 colic, n = 1; grade 1 hypersensitivity, n = 1; grade 2 hypersensitivity, n = 2; grade 5 hypersensitivity, n = 1). Higher grade adverse effects most commonly were associated with doxorubicin administration (n = 4), including 1 horse that died 18 hours post-administration. Conclusions: Chemotherapy can be used successfully for treatment of horses with lymphoma. Adverse effects, most commonly mild, occurred in approximately two-thirds of treated horses.
© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2019-01-12 PubMed ID: 30636061PubMed Central: PMC6430950DOI: 10.1111/jvim.15411Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research seeks to understand the long-term outcomes of horses diagnosed with lymphoma and treated with chemotherapy. The retrospective study uses data from 15 horses, finding that most responded to treatment with varying degrees of efficacy, and although there were some adverse effects, chemotherapy can potentially be a successful treatment technique for equine lymphoma.

Research Methods

  • The researchers conducted a retrospective study, meaning they used existing data rather than collecting new data.
  • The data was found through a medical record search and from cases reported on the ACVIM listserv – an online community for veterinary internal medicine specialists.
  • The study was specifically looking at horses that were treated with chemotherapy for lymphoma.

Study Findings

  • Out of 15 cases identified for the study, 5 horses (33.3%) achieved complete remission, 9 (60%) had a partial response, and the disease remained stable in one horse.
  • The overall response rate for chemotherapy treatment was 93.3% (14 out of 15).
  • The median survival time post-diagnosis and treatment was reported at 8 months (ranging from 1-46 months).

Adverse Effects of Chemotherapy

  • The study also documented the kind and severity of adverse effects the horses experienced as a result of chemotherapy, using a grading system developed by the Veterinary Cooperative Oncology Group.
  • A total of 14 adverse effects were noted among 9 horses, ranging in severity from alopecia (hair loss) and neutropenia (low neutrophil count) to neurotoxicity and hypersensitivity.
  • The more severe adverse effects were most commonly linked to the administration of the chemotherapy drug Doxorubicin, including one horse that died 18 hours after the treatment.

Conclusion

  • The researchers concluded that chemotherapy can be a successful form of treatment for horses with lymphoma, with a majority of the horses studied showing either partial or complete remission of the disease.
  • Approximately two-thirds of the treated horses experienced adverse effects of varying severity but the study suggests these are mostly mild.
  • While the study provides some insight into the potential benefits of chemotherapy for horses with lymphoma, further research is advised to continue to understand the potential risks and efficacy.

Cite This Article

APA
Luethy D, Frimberger AE, Bedenice D, Byrne BS, Groover ES, Gardner RB, Lewis T, MacDonald VS, Proctor-Brown L, Tomlinson JE, Rassnick KM, Johnson AL. (2019). Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991-2017). J Vet Intern Med, 33(2), 953-960. https://doi.org/10.1111/jvim.15411

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 33
Issue: 2
Pages: 953-960

Researcher Affiliations

Luethy, Daniela
  • Department of Clinical Studies-New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania.
Frimberger, Angela E
  • Veterinary Oncology Consultants, Wauchope, New South Wales, Australia.
Bedenice, Daniela
  • Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts.
Byrne, Barbara S
  • Department of Pathology, Microbiology and Immunology, University of California Davis School of Veterinary Medicine, Davis, California.
Groover, Erin S
  • Department of Clinical Sciences, Auburn University College of Veterinary Medicine, Auburn, Alabama.
Gardner, Rachel B
  • B.W. Furlong & Associates, Oldwick, New Jersey.
Lewis, Trisha
  • Lewis Veterinary Services, Maple Park, Illinois.
MacDonald, Valerie S
  • University of Saskatchewan Western College of Veterinary Medicine, Saskatoon, Saskatchewan, Canada.
Proctor-Brown, Lauren
  • Baker Institute for Animal Health, Cornell University College of Veterinary Medicine, Ithaca, New York.
Tomlinson, Joy E
  • Baker Institute for Animal Health, Cornell University College of Veterinary Medicine, Ithaca, New York.
Rassnick, Kenneth M
  • Veterinary Medical Center of New York, East Syracuse, New York.
Johnson, Amy L
  • Department of Clinical Studies-New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania.

MeSH Terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Equidae
  • Female
  • Horse Diseases / drug therapy
  • Horses
  • Lymphoma / drug therapy
  • Lymphoma / veterinary
  • Male
  • Remission Induction
  • Retrospective Studies
  • Treatment Outcome

Conflict of Interest Statement

Authors declare no conflict of interest.

References

This article includes 28 references
  1. Knowles EJ, Tremaine WH, Pearson GR, Mair TS. A database survey of equine tumours in the United Kingdom.. Equine Vet J 2016;48(3):280‐284.
    pubmed: 25594351
  2. Durham AC, Pillitteri CA, San Myint M, Valli VE. Two hundred three cases of equine lymphoma classified according to the World Health Organization (WHO) classification criteria.. Vet Pathol 2013;50(1):86‐93.
    pubmed: 22700849
  3. Saulez MN, Schlipf JW, Cebra CK, McDonough SP, Bird KE. Use of chemotherapy for treatment of a mixed‐cell thoracic lymphoma in a horse.. J Am Vet Med Assoc 2004;224(5):733‐738. 699.
    pubmed: 15002812
  4. Doyle AJ, MacDonald VS, Bourque A. Use of lomustine (CCNU) in a case of cutaneous equine lymphoma.. Can Vet J 2013;54(12):1137‐1141.
    pmc: PMC3831386pubmed: 24293673
  5. Vail DM, Michels GM, Khanna C, Selting KA, London CA. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)—a Veterinary Cooperative Oncology Group (VCOG) consensus document.. Vet Comp Oncol 2010;8(1):28‐37.
    pubmed: 20230579
  6. Byrne BA, Yvorchuk‐St. Jean K, Couto CG, Kohn CW. Successful management of lymphoproliferative disease in two pregnant mares.. Proceedings of the 11th Annual Conference Veterinary Cancer Society 1991;8‐9.
  7. Larsdotter S, Nostell K, von Euler H. Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma.. Vet J 2015;205(2):313‐316.
    pubmed: 25744802
  8. . Veterinary cooperative oncology group—common terminology criteria for adverse events (VCOG‐CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.. Vet Comp Oncol 2016;14(4, 4):417‐446.
    pubmed: 28530307
  9. Théon AP, Pusterla N, Magdesian KG, Wittenburg L, Marmulak T, Wilson WD. A pilot phase II study of the efficacy and biosafety of doxorubicin chemotherapy in tumor‐bearing equidae.. J Vet Intern Med 2013;27(6):1581‐1588.
    pubmed: 24107145
  10. Miller MA, Moore GE, Bertin FR, Kritchevsky JE. What's new in old horses? Postmortem diagnoses in mature and aged Equids.. Vet Pathol 2016;53(2, 2):390‐398.
    pubmed: 26459516
  11. van Den HR, Franken P. Clinical aspects of lymphosarcoma in the horse: a clinical report of 16 cases.. Equine Vet J 1983;15(1):49‐53.
    pubmed: 6687455
  12. Meyer J, Delay J, Bienzle D. Clinical, laboratory, and histopathologic features of equine lymphoma.. Vet Pathol 2006;43(6):914‐924.
    pubmed: 17099148
  13. Miller CA, Durham AC, Schaffer PA, Ehrhart EJ, Powers BE, Duncan CG. Classification and clinical features in 88 cases of equine cutaneous lymphoma.. J Vet Diagn Invest 2015;27(1):86‐91.
    pubmed: 25525142
  14. Zandvliet M. Canine lymphoma: a review.. Vet Q 2016;36(2):76‐104.
    pubmed: 26953614
  15. Chan CM, Frimberger AE, Moore AS. Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003‐2015).. Vet Dermatol 2018;29(2):154‐e59.
    pubmed: 28983988
  16. Zandvliet M, Rutteman GR, Teske E. Prednisolone inclusion in a first‐line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results.. Vet J 2013;197(3):656‐661.
    pubmed: 23746872
  17. Théon AP, Pusterla N, Magdesian KG, Wilson WD. Phase I dose escalation of doxorubicin chemotherapy in tumor‐bearing equidae.. J Vet Intern Med 2013;27(5):1209‐1217.
    pubmed: 23889748
  18. Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Anthracyclines.. Cancer Chemother Biol Response Modif 2003;21:29‐40.
    pubmed: 15338739
  19. Syrigou E, Makrilia N, Koti I, Saif MW, Syrigos KN. Hypersensitivity reactions to antineoplastic agents: an overview.. Anticancer Drugs 2009;20(1):1‐6.
    pubmed: 19342995
  20. Blake MK, Carr BJ, Mauldin GE. Hypersensitivity reactions associated with L‐asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007–2012.. Can Vet J 2016;57(2):176‐182.
    pmc: PMC4712998pubmed: 26834270
  21. Chanan‐Khan A, Szebeni J, Savay S. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.. Ann Oncol 2003;14(9):1430‐1437.
    pubmed: 12954584
  22. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem.. Drugs 1991;42(5):781‐795.
    pubmed: 1723374
  23. Vander Werf K, Davis E. Disease remission in a horse with EHV‐5‐associated lymphoma.. J Vet Intern Med 2013;27(2, 2):387‐389.
    pubmed: 23458852
  24. Azim HA, Santoro L, Bociek RG, Gandini S, Malek RA, Azim HA. High dose intensity doxorubicin in aggressive non‐Hodgkin's lymphoma: a literature‐based meta‐analysis.. Ann Oncol 2010;21(5):1064‐1071.
    pubmed: 19850640
  25. Ma X, Xu Y, Zhang W. High‐intensity chemotherapy is associated with better prognosis in young patients with high‐risk diffuse large B‐cell lymphoma: a 10‐year single‐center retrospective cohort study.. Med Sci Monit 2016;22:1792‐1800.
    pmc: PMC4913830pubmed: 27232105
  26. Autio K, Rassnick KM, Bedford‐Guaus SJ. Chemotherapy during pregnancy: a review of the literature.. Vet Comp Oncol 2007;5(2):61‐75.
    pubmed: 19754790
  27. Azim HA, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors.. Cancer Treat Rev 2010;36(2):110‐121.
    pubmed: 20018452
  28. McGovern KF, Lascola KM, Davis E, Fredrickson RL, Tan R. T‐cell lymphoma with immune‐mediated anemia and thrombocytopenia in a horse.. J Vet Intern Med 2011;25(5):1181‐1185.
    pubmed: 21985147

Citations

This article has been cited 8 times.
  1. Ostendarp C, Barton AK. Intraocular Tumors in Horses: Diagnosis, Tumor Classification, Oncologic Assessment and Therapy. Vet Sci 2025 Oct 17;12(10).
    doi: 10.3390/vetsci12101006pubmed: 41150147google scholar: lookup
  2. Paraschou G, Xue C, Egan R, Bolfa P. Multicentric lymphoma in a donkey with intestinal and bone marrow involvement. BMC Vet Res 2024 Feb 15;20(1):57.
    doi: 10.1186/s12917-024-03903-5pubmed: 38360691google scholar: lookup
  3. Wensley FM, Berryhill EH, Magdesian KG. Association of globulin concentrations with prognosis in horses with lymphoma. Front Vet Sci 2022;9:1086010.
    doi: 10.3389/fvets.2022.1086010pubmed: 36699338google scholar: lookup
  4. Drozdzewska K, Gehlen H. Markers for internal neoplasia in the horse. Vet Med Sci 2023 Jan;9(1):132-143.
    doi: 10.1002/vms3.1042pubmed: 36495211google scholar: lookup
  5. Kondratjeva J, Julien F, Coutelier C, Humeau L, Moog F, Combarros D, Fourquaux I, Pressanti C, Delverdier M, Moore PF, Cadiergues MC. Cutaneous epitheliotropic T-cell lymphoma in a donkey - a case report. BMC Vet Res 2022 Jul 11;18(1):267.
    doi: 10.1186/s12917-022-03365-7pubmed: 35821128google scholar: lookup
  6. Wang L, Unger L, Sharif H, Eriksson S, Gerber V, Rönnberg H. Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma. BMC Mol Cell Biol 2021 Dec 14;22(1):59.
    doi: 10.1186/s12860-021-00399-xpubmed: 34906077google scholar: lookup
  7. Moore C, Stefanovski D, Luethy D. Clinical performance of a commercially available thymidine kinase 1 assay for diagnosis of lymphoma in 42 hospitalized horses (2017-2020). J Vet Intern Med 2021 Sep;35(5):2495-2499.
    doi: 10.1111/jvim.16239pubmed: 34359096google scholar: lookup
  8. Wright S. Highlights of recent clinically relevant papers. Equine Vet Educ 2019 Aug;31(8):394-395.
    doi: 10.1111/eve.13139pubmed: 32313398google scholar: lookup
Subscribe to our newsletter
Join 100,113 horse owners like you who receive our email updates on horse health and nutrition.